Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis

Neurologic Clinics

Volumn 33, Issue 4, 2015, Pages 889-908

  Jackson, Carlayne E ^a   McVey, April L ^b   Rudnicki, Stacy ^c   Dimachkie, Mazen M ^b   Barohn, Richard J ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Constipation; Edema; Laryngospasm; Noninvasive ventilation; Pseudobulbar affect; Secretion management; Sialorrhea; Urinary urgency

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS QUINIDINE; GLYCOPYRRONIUM BROMIDE; GUAIFENESIN; HYOSCYAMINE; IPRATROPIUM BROMIDE; METOPROLOL; MIRTAZAPINE; MODAFINIL; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; PLACEBO; PNEUMOCOCCUS VACCINE; PROPRANOLOL; QUINIDINE SULFATE; SCOPOLAMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLPIDEM TARTRATE;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; BITE; BODY WEIGHT DISORDER; CHEEK BITING; COGNITIVE THERAPY; CONSTIPATION; DENTAL PROTECTOR; DEPRESSION; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; EDEMA; ENDOTRACHEAL INTUBATION; ENTERIC FEEDING; EXERCISE; FATIGUE; FLUID THERAPY; HOSPITAL BED; HUMAN; HYPERSALIVATION; JAW DISEASE; JAW QUIVERING; LARYNX SPASM; MALNUTRITION; MULTICENTER STUDY (TOPIC); NONINVASIVE VENTILATION; OXYGEN THERAPY; PAIN; PALLIATIVE THERAPY; PATIENT POSITIONING; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSEUDOBULBAR PALSY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SPASTICITY; STOMACH TUBE; STRETCHING EXERCISE; SYMPTOM; TERMINAL CARE; COMPLICATION; DISEASE MANAGEMENT; NURSING;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE MANAGEMENT; HUMANS; TERMINAL CARE;

EID: 84945963943     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2015.07.010     Document Type: Review

References (103)

1. Forshew D.A., Bromberg M.B. A survey of clinicians' practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:258-263.
2. Sufit R., Miller R., Mitsumoto H., et al. Prevalence and treatment outcomes of sialorrhea in amyotrophic lateral sclerosis patients as assessed by the ALS patient care database. Ann Neurol 1999, 46:506.
3. Miller R.G., Rosenberg J.A., Gelinas D.F., et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999, 52:1311-1323.
4. Jackson C.E., Rosenfeld J. Symptomatic pharmacotherapy: bulbar and constitutional symptoms. Amyotrophic lateral sclerosis 2006, 649-664. Taylor & Francis Group, New York. Mitsumoto, Przedborski, Gordon (Eds.).
5. Bradley W.G., Anderson F., Bromberg M., et al. Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology. Neurology 2001, 57:500-504.
6. Portis M., Gamba M., Bertaccji G., et al. Treatment of sialorrhea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 2001, 70:538-540.
7. Giess R., Naumann M., Werner E., et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000, 69:121-123. [see comment].
8. Rowe D., Erjavec S. An open-label pilot study of intra-parotid botulinum toxin A injections in the treatment of sialorrhea in motor neuron disease. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:53-54.
9. Bhatia K.P., Munchau A., Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 1999, 67:697.
10. Jackson C.E., Gronseth G., Rosenfeld J., et al. Randomized double-blind study of botulinum toxin type B in ALS patients. Muscle Nerve 2009, 39:137-143.
11. Harriman M., Morrison M., Hay J., et al. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001, 30:242-249.
12. Andersen P.M., Gronberg H., Franze L., et al. External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbar paresis. J Neurol Sci 2001, 191:111-114.
13. Miller R.G., Jackson C.E., Kasarskis E.J., et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) report of the quality standards Subcommittee of the American Academy of Neurology. Neurology 2009, 73:1227-1233.
14. Marin M.G. Pharmacology of airway secretion. Pharmaocl Rev 1986, 38:273-289.
15. Newall A.R., Orser R., Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996, 139:43-44.
16. Radunovic A., Mitsumotor H., Leigh P.N. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007, 6(10):913-925.
17. McCullagh S., Moore M., Gawel M., et al. Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction. J Neurol Sci 1999, 169:43-48.
18. Brooks B.R., Thisted R.A., Appel S.H., et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004, 63:1364-1370.
19. Arnulf I., Similowski T., Salachas F., et al. Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2000, 161:849-856.
20. Czaplinski A., Yen A.A., Appel S.H. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006, 77:390-392.
21. Jackson C.E., Rosenfeld J., Moore D.H., et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001, 191:75-78.
22. Lechtzin N., Wiener C.M., Shade D.M., et al. Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis. Chest 2002, 121:436-442.
23. Varrato J., Siderowf A., Damiano P., et al. Postural change of forced vital capacity predicts some respiratory symptoms in ALS. Neurology 2001, 57:357-359.
24. Vaszar L.T., Weinacker A.B., Henig N.R., et al. Ethical issues in the long-term management of progressive degenerative neuromuscular diseases. Semin Respir Crit Care Med 2002, 23:307-314.
25. Hull J., Aniapravan R., Chan E., et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. Thorax 2012, 67(Suppl 1):i1-i40.
26. Miller R.G., Jackson C.E., Kasarskis E.J., et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review) report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2009, 73:1218-1226.
27. Bourke S.C., Tomlinson M., Williams T.L., et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006, 5:140-147.
28. Bourke S.C., Bullock R.E., Williams T.L., et al. Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology 2003, 61:171-177.
29. Butz M., Wollinsky K.H., Wiedemuth-Catrinescu U., et al. Longitudinal effects of noninvasive positive-pressure ventilation in patients with amyotrophic lateral sclerosis. Am J Phys Med Rehabil 2003, 82:597-604.
30. Lyall R.A., Donaldson N., Fleming T., et al. A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 2001, 57:153-156.
31. Pinto A., de Carvalho M., Evangelista T., et al. Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:31-35.
32. Aboussouan L.S., Khan S.U., Meeker D.P., et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997, 127:450-453.
33. Jackson C.E., Lovitt S., Gowda N., et al. Factors correlated with NPPV use in ALS. Amyotroph Lateral Scler 2006, 7:80-85.
34. Olney R.K., Murphy J., Forshew D., et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005, 65:1774-1777.
35. Gruis K.L., Brown D.L., Schoennemann A., et al. Predictors of noninvasive ventilation tolerance in patients with amyotrophic lateral sclerosis. Muscle Nerve 2005, 32:808-811.
36. Bach J.R. Amyotrophic lateral sclerosis: predictors for prolongation of life by noninvasive respiratory aids. Arch Phys Med Rehabil 1995, 76:828-832.
37. Tzeng A.C., Bach J.R. Prevention of pulmonary morbidity for patients with neuromuscular disease. Chest 2000, 118:1390-1396.
38. Mangera Z., Panesar G., Makker H. Practical approach to management of respiratory complications in neurological disorders. Int J Gen Med 2012, 5:255-263.
39. Garpestad E., Hill N. Noninvasive ventilation for patients with neuromuscular disease and acute respiratory failure. Chest 2008, 133:315. [author reply: 315].
40. Perrin C., Unterborn J.N., Ambrosio C.D., et al. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve 2004, 29:5-27.
41. Park J.H., Kang S.W., Lee S.C., et al. How respiratory muscle strength correlates with cough capacity in patients with respiratory muscle weakness. Yonsei Med J 2010, 51:392-397.
42. McElhiney M.C., Rabkin J.G., Gordon P.H., et al. Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry 2009, 80:1146-1149.
43. Lo Coco D., La Bella V. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. Eur J Neurol 2012, 19:760-763.
44. Ramirez C., Piemonte M.E., Callegaro D., et al. Fatigue in amyotrophic lateral sclerosis: frequency and associated factors. Amyotroph Lateral Scler 2008, 9:75-80.
45. Bensimon G., Lacomblez L., Meininger V.A. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994, 330:585-591.
46. Lou J.-S., Reeves A., Benice T., et al. Fatigue and depression are associated with poor quality of life in ALS. Neurology 2003, 60:122-123.
47. Rabkin J.G., Gordon P.H., McElhiney M., et al. Modafinil treatment of fatigue in patients with ALS: a placebo controlled study. Muscle Nerve 2009, 39:297-303.
48. Mascaritioli M., Kushta I., Molfino A., et al. Nutritional and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition 2012, 28:959-966.
49. Desport J.C., Preux P.M., Magy L., et al. Factors associated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2001, 74:328-334.
50. Dupuis L., Pradat P.-F., Ludolph A.C., et al. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011, 10:75-82.
51. Kasarskis E.F., Mendiondo M.S., Matthews D.E., et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr 2014, 99:792-803.
52. Limousin N., Blasco H., Corcia P., et al. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. J Neurol Sci 2010, 297:36-39.
53. Shimuzu T., Nagaoka U., Nakayama Y., et al. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler 2012, 13:363-366.
54. Jawaid A., Murphy S.B., Wilson A.M., et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler 2010, 11:542-548.
55. Paganoni S., Deng J., Jaffa M., et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011, 44:20-24.
56. Gallo V., Wark P., Jenab M., et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis. Neurology 2013, 80:829-838.
57. Katzberg H.D., Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor. Neuron disease. Cochrane Database Syst Rev 2011, (1). CD004030.
58. Chiò A., Bottacchi E., Buffa C., PARALS, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcomes and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006, 77:948-950.
59. Czaplinski A., Yen A.A., Simpson E.R., et al. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?. Arch Neurol 2006, 63:1139-1143.
60. Forbes R.B., Colvisse S., Swingler R.J., Scottish Motor Neurone Disease Research Group Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease - a record linkage study from the Scottish Motor Neuron Disease Registry. J Neurol 2004, 251(7):813-817.
61. Mitchell J.D., O'Brien M.R., Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler 2006, 7(2):67-71.
62. Zhang M., Hubbard J., Rudnicki S.A., et al. Survey of current enteral nutrition practices in treatment of amyotrophic lateral sclerosis. ESPEN J 2013, 8:e25-e28. Available at:. http://www.sciencedirect.com/science/article/pii/S2212826312000619.
63. Desport J.C., Preux P.M., Truong C.T., et al. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1(2):91-96.
64. Mazzini L., Corra T., Zaccala M., et al. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurolog y 1995, 242(10):695-698.
65. Chiò A., Galetti R., Finocchiaro C., et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry 2004, 75:645-646.
66. Allen J.A., Chen R., Ajroud-Driss S., et al. Gastrostomy tube placement by endoscopy vs radiologic methods in patients with ALS: a retrospective study of complications and outcomes. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(4):308-314.
67. Stanich P., Chiapetta A., Oliviera A., et al. Nutritional supplementation in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002, 3:119.
68. Silva L.B., Mourao L.F., Silva A.A., et al. Effect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patients. Arq Neuropsiquiatr 2010, 68(2):263-268.
69. Dorst J., Cypionka J., Ludolph A.C. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(7-8):533-536.
70. Wills A.M., Hubbard J., Macklin E.A., et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014, 383(14):6065-6072.
71. Czell D., Bauer M., Binek J., et al. Outcomes of percutaneous endoscopic gastrostomy tube insertion in respiratory impaired amyotrophic lateral sclerosis patients under noninvasive ventilation. Respir Care 2013, 58(5):838-844.
72. Pizziementia A., Aragona M., Onesti E., et al. Depression, pain, and quality of life in patients with amyotrophic lateral sclerosis: a cross sectional study. Funct Neurol 2013, 28(2):115-119.
73. Chio A., Canosa A., Gallo S., et al. Pain in amyotrophic lateral sclerosis: a population-based controlled study. Eur J Neurol 2012, 19(4):551-555.
74. Ajroud-Driss S., Casey P., Heller S., et al. Prevalence and characteristics of pain in early and late stages of ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(5-6):369-372.
75. Pagnini F., Lunetta C., Banfi P., et al. Pain in amyotrophic lateral sclerosis: a psychological perspective. Neurol Sci 2012, 33(5):1193-1196.
76. Newrick P.G., Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1985, 48:838-840.
77. Brettschneider J., Kurent J., Ludolph A. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013, (6). [review], CD005226.
78. McClelland S., Bethoux F.A., Boulis N.M., et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve 2008, 37(3):396-398.
79. Drory V.E., Goltsman E., Reznik J.G., et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001, 191:133-137.
80. Bedlack R.S., Pastula D.M., Hawes J., et al. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 2009, 10(4):210-215.
81. Winterholler M.G., Heckman J.G., Hecht M., et al. Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin. Neurology 2002, 58:502-503.
82. Restivo D.A., Lanza S., Marchese-Raguna R., et al. Improvement of masseter spasticity by botulinum toxin facilitates PEG placement in amyotrophic lateral sclerosis. Gastroenterology 2002, 123(5):1749-1750.
83. Anderson P.M., Abrahams S., Borasio G., et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol 2012, 19:360-375.
84. Sperfeld A.D., Hanemann O.C., Ludolph A.C., et al. Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology 2005, 64(4):753-754.
85. Kuhnlein P., Gdynia H.J., Sperfeld A.D., et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol 2008, 4(7):366-374.
86. Jenkins T.M., Hollinger H., McDermott C.J. The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol 2014, 27:524-531.
87. Simmons Z. Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death. Neurologist 2005, 11(5):257-270.
88. Borasio G.D., Oliver D. The control of other symptoms. Amyotrophic lateral sclerosis 2000, 72-79. Oxford University Press, Oxford (United Kingdom). D. Oliver, G.D. Borasio, D. Walsh (Eds.).
89. Piccione E.A., Sletten D.M., Staff N.P., et al. Autonomic system and ALS. Muscle Nerve 2015, 51(5):676-679.
90. Nubling G.S., Bauer M., Bauer R.M., et al. Increased prevalence of bladder and intestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014, 15(3-4):174-179.
91. Rocha J.A., Reis C., Simoes F., et al. Diagnostic investigation and multidisciplinary management in motor neuron disease. J Neurol 2005, 252:1435-1447.
92. Atassi N., Cook A., Pineda C.M., et al. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011, 12(2):109-112.
93. Rabkin J.G., Goetz R., Factor-Litvak P., The ALS Cosmos Study Group, et al. Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 2015, 16(3-4):265-273.
94. Kurt A., Nijboer F., Maatuz T., et al. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs 2007, 21(4):279-291.
95. Chen D., Xiaoyan G., Sheng Z., et al. Depression and anxiety in amyotrophic lateral sclerosis: correlations between the distress of patients and caregivers. Muscle Nerve 2015, 51:353-357.
96. Taylor L., Wicks P., Leigh P.N., et al. Prevalence of depression in amyotrophic lateral sclerosis and other motor disorders. Eur J Neurol 2010, 17:1047-1053.
97. Vignola A., Guzzo A., Calvo A., et al. Anxiety undermines quality of life in ALS patients and caregivers. Eur J Neurol 2008, 15(11):1231-1236.
98. Tagami M., Kimura F., Nakajima H., et al. Tracheostomy and invasive ventilation in Japanese ALS patients: decision making and survival analysis: 1990-2010. J Neurol Sci 2014, 344(1-2):158-164.
99. Ganzini L., Johnston W.S., Silveira M.J. The final month of life in patients with ALS. Neurology 2002, 59:428-431.
100. Blackhall L.J. Amyotrophic lateral sclerosis and palliative care: where we are, and the road ahead. Muscle Nerve 2012, 45:311-318.
101. Rabkin J., Ogino M., Goetz R., et al. Tracheostomy with invasive ventilation for ALS patients: neurologist's roles in the US and Japan. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(2):116-123.
102. Hayashi H., Oppenheier E.A. ALS patients on TPPV: totally locked-in state, neurologic findings and ethical implications. Neurology 2003, 61:135-137.
103. Dreyer P.S., Felding M., Klitnaes C.S., et al. Withdrawal of invasive home mechanical ventilation in patients with advanced amyotrophic lateral sclerosis: ten years of Danish experience. J Palliat Med 2012, 15(2):205-209.